From the Research
The standard dose of Eliquis (apixaban) for post femoral bypass prophylaxis is typically 2.5 mg taken orally twice daily, as supported by the most recent and highest quality study available 1.
Key Considerations
- This regimen should generally be started 12-24 hours after surgery once hemostasis has been established.
- The recommended duration of prophylaxis is usually 10-14 days, though some patients may require extended prophylaxis for up to 35 days depending on their individual risk factors for venous thromboembolism.
- Dose adjustment is necessary for patients with severe renal impairment (creatinine clearance 15-29 mL/min), reducing to 2.5 mg once daily.
- Apixaban should be used cautiously in patients with other anticoagulants, antiplatelet drugs, or NSAIDs due to increased bleeding risk.
Mechanism and Monitoring
- The medication works by selectively inhibiting Factor Xa, preventing thrombin formation and clot development.
- Regular monitoring of the patient for signs of bleeding is essential, and the medication should be temporarily discontinued prior to invasive procedures.
- Patients should be advised to take the medication at the same times each day and not to skip doses, as this could increase thrombosis risk.
Evidence Base
- The study by 1 provides the most recent and highest quality evidence for the use of apixaban in post femoral bypass prophylaxis, demonstrating its efficacy and safety in preventing recurrent venous thromboembolism.
- While other studies, such as 2, 3, 4, and 5, provide additional information on the use of apixaban in various clinical settings, the study by 1 is the most relevant and informative for guiding clinical practice in this specific context.